Yaping Shou, M.D., Ph.D., is a Venture Partner at Lilly Asia Ventures (LAV). Prior to joining LAV, Yaping was the chief medical officer of Trillium Therapeutics, and prior to that, the executive medical director with Takeda Pharmaceuticals. Yaping has over 20 years of global clinical development experience in both pharma (GlaxoSmithKline, Novartis, and Takeda) and biotech (Trillium) companies. She has made critical contributions to the development and approval of multiple oncology drugs. Yaping holds a MD degree from Zhejiang University School of Medicine and a PhD degree in cellular and molecular biology from Drexel University. She also received post-doctoral fellowship training at the Genetic Branch of NCI.